CorImmune Functions as Radiation Mitigator

LEXINGTON, Kan.—CorImmune proved to be effective as a radiation mitigator when administered after radiation injury, according to a recent study at the Veterans Affairs Medical Center and University of Kentucky Medical Center, Lexington (IntJ Radiat Biol. 2008;84(2):139-49) (DOI:10.1080/09553000701797070). Mice received total body irradiation (TBI) followed by treatment with CorImmune (from Xenos Nutraceuticals Inc.) or a normal saline (control). CorImmune was administered beginning two hours after a lethal dose of TBI; There was a 55-percent improvement in survival in the treatment group vs. zero percent in the saline control (P<0.0001). The supplement increased normal leukocyte levels in a dose-dependent fashion. Animals treated with sub-lethal TBI and monitored for blood leukocyte recovery exhibited a return to normal baseline three weeks after TBI injury. In contrast, only 50 percent returned to normal baseline in the saline control group (P<0.01). CorImmune also stimulated immune lymphocyte proliferation by nearly two-fold. CorImmune significantly increased animal survival after a lethal dose of radiation, accelerated leukocyte recovery and stimulated immune lymphocyte proliferation.